Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
To investigate safety, tolerability, PK and PD of BI 655075 and to establish the BI 655075 dose(s) effective to reverse prolongation of blood coagulation time by dabigatran
Epistemonikos ID: a0de7cb7af4c482a910f3609f76855f0764f1ebb
First added on: May 11, 2024